Pharmacogenetics at 50: Genomic Personalization Comes of Age

See allHide authors and affiliations

Science Translational Medicine  22 Jan 2014:
Vol. 6, Issue 220, pp. 220ps1
DOI: 10.1126/scitranslmed.3005237

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The study of the genetics of drug responses has a long history but has provided only a few examples of gene variants that are relevant clinically. Here, we discuss the current state of the pharmacogenomics field with emphasis on the potential of data generated through drug development in order to shed new light on genetic variants predictive of therapeutic outcomes—and likewise the potential of pharmacogenomics to improve clinical trial design. We note some examples in which data from clinical trials have already provided clear pharmacogenomic insights and suggest ways in which genomic technology might be used successfully in drug development.

View Full Text

Stay Connected to Science Translational Medicine

Editor's Blog